Moreover, inhibitors that target the downstream signaling cascade of KRAS, including the mitogen-activated protein kinase (MEK) inhibitor selumetinib, exhibit limited efficacy in CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.